The impact of exposure to biomass smoke versus cigarette smoke on inflammatory markers and pulmonary function parameters in patients with chronic respiratory failure

Int J Chron Obstruct Pulmon Dis. 2018 Apr 18:13:1261-1267. doi: 10.2147/COPD.S162658. eCollection 2018.

Abstract

Purpose: The aim of this study was to evaluate the impact of exposure to biomass smoke vs cigarette smoke on serum inflammatory markers and pulmonary function parameters in patients with chronic respiratory failure (CRF).

Patients and methods: A total of 106 patients with CRF divided into age and gender-matched groups of cigarette-smoke exposure (n=55, mean [SD] age: 71.0 [12.0] years, 92.7% were females) and biomass smoke exposure (n=51, mean [SD] age: 73.0 [11.0] years, 94.1% were females) were included in this retrospective study. Data on patient demographics (age and gender), inflammatory markers, including neutrophil-to-lymphocyte ratio, C-reactive protein, platelet/mean platelet volume ratio, arterial blood gas analysis, and pulmonary function test findings, including forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC were obtained from medical records.

Results: Carbon dioxide partial pressure levels were significantly higher in the biomass smoke exposure than in the cigarette smoke exposure group (mean [SD] 51.0 [8.0] vs 47.0 [8.0] mmHg, p=0.026, respectively). Spirometry revealed similarly low levels for FEV1 (%) (38.0 [16.0] vs 40.0 [12.0]%) and FVC (%) (45.0 [19.0] vs 39.0 [19.0]%) in cigarette-smoke and biomass smoke exposure groups, whereas biomass smoke exposure was associated with significantly higher FEV1/FVC (75.0 [14.0] vs 58.0 [12.0]%, p=0.001), lower FVC (mL) (mean [SD] 744.0 [410.0] vs 1,063.0 [592.0] mL, p=0.035) and lower percentage of patients with FEV1/FVC <70% (36.8% vs 82.0%, p<0.001) than cigarette smoke exposure.

Conclusion: Our findings indicate similarly increased inflammatory markers and abnormally low pulmonary function test findings in both biomass smoke exposure and cigarette smoke exposure groups, emphasizing the adverse effects of biomass smoke exposure on lungs to be as significant as cigarette smoke exposure. Association of biomass smoke exposure with higher likelihood of FEV1/FVC ratio of >70% and more prominent loss of vital capacity than cigarette smoke exposure seems to indicate the likelihood of at least 18 years of biomass exposure to be sufficiently high to be responsible for both obstructive and restrictive pulmonary diseases.

Keywords: biomass exposure; chronic respiratory failure; cigarette smoke; inflammatory markers; spirometry.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Biomass*
  • Chronic Disease
  • Cigarette Smoking / adverse effects*
  • Female
  • Forced Expiratory Volume
  • Humans
  • Inflammation Mediators / blood*
  • Lung / metabolism
  • Lung / physiopathology*
  • Lymphocyte Count
  • Male
  • Medical Records
  • Middle Aged
  • Platelet Count
  • Prognosis
  • Respiratory Insufficiency / blood
  • Respiratory Insufficiency / diagnosis
  • Respiratory Insufficiency / etiology*
  • Respiratory Insufficiency / physiopathology
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Smoke / adverse effects*
  • Spirometry
  • Time Factors
  • Vital Capacity

Substances

  • Biomarkers
  • Inflammation Mediators
  • Smoke